Oxandrolone
Other Names
- Oxandrin
- Anavar
General
- Classified as an androgenic-anabolic steroid used to build muscle mass and treat catabolic/wasting conditions
- Administered orally
- Derived from DHT.
- Testosterone converts to DHT via 5-alpha reductase (the popular hair-loss medication finasteride, works by blocking 5-akpha reductase to reduce DHT levels)
- Used as a performance-enhancing drug in many sports
- Especially popular in bodybuilding and powerlifting
Performance Enhancing Effects
- Muscle growth
- Via stimulation of protein synthesis; protein breakdown unchanged [1]
- Increased utilization of intracellular amino acids
- 6x the anabolic activity of testosterone in assays with no estrogenic or pregestational activity and significantly less androgenicity [2]
Medical Indications
- FDA approval:
- Administration improves long-term recovery of severely burned children
- Improvements in height, bone mineral content, cardiac work, and muscle strength [4]
- Benefits occurred for up to 5 years post burn
- Also been used for Duchenne muscular dystrophy, AIDS wasting syndrome, high quad pulmonary function
Contraindications
- Known or suspected cancers[3]
- Carcinoma of the prostate or male breast
- Carcinoma of the breast in females with hypercalcemia
- Anabolic steroids may stimulate osteolytic bone resorption
- Pregnancy due to masculinization of the fetus (category X)
- Hypercalcemia
- Nephrotic syndrome
Adverse Reactions
- May increase sensitivity to oral anticoagulants like warfarin (requires close monitoring)[3]
- Hepatic tumors
- Liver cell tumors have been reported in patients receiving long-term androgenic anabolic steroids in higher doses and withdrawal of steroids did not always lead to regression of tumor
- Patients with moderate to severe COPD should be monitored closely for COPD exacerbations and fluid retention.
- Adverse reactions seen with the use of androgenic anabolic steroids:
Males:
- Phallic enlargement
- Increased frequency/persistence of erection
- Inhibition of testicular function
- Testicular atrophy
Females:
- Clitoral enlargement
- Menstrual irregularities
- Deepening of the voice
- Male pattern baldness
By system/organ
- CNS: habituation, excitation, insomnia, depression, changes in libido
- Hematologic: bleeding when used with anticoagulants (see above)
- Breast: gynecomastia
- Hair: hirsutism
- Skin: acne
- Skeletal: premature closure of epiphyses
- FLuid/electrolytes: edema, retention of sodium, chloride, potassium, phosphate, and calcium
- Metabolic/endocrine: decreased glucose tolerance, increased creatinine excretion, increased creatine phosphokinase levels
Pharmacology
- Agonist of androgen receptor
- Mechanism of action is like that of testosterone:
- Oxandrolone binds to androgen receptors in the cytoplasm of muscle cells
- This complex translocates to the nucleus
- Binds to androgen-receptor binding sites that induce the transcription of genes that are responsible for muscle growth and repair
- Oral bioavailability is 97% [5]
- Primarily metabolized by the kidneys and the liver to a lesser extent (therefore less hepatotoxic compared to other anabolics)[5]
- Elimination half-life 9.4-10.4 hours and up to 13.3 hours in the elderly [5]
WADA Considerations
- Prohibited at all times by WADA (in and out of competition)
- Classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and assigned to schedule 3 (non-narcotic) [3]
Testing
- Blood or urine testing may be used
- Long-term use of steroids suppresses endogenous steroids levels in urine samples
- May be the earliest indication of steroid use [6]
- Newer technologies have lengthened the drug detection window by testing for steroid metabolites [6]
- Many athletes are caught years later due to advancements in technology
See Also
References
- ↑ Sheffield-Moore, M. 1999. “Short-Term Oxandrolone Administration Stimulates Net Muscle Protein Synthesis in Young Men.” Journal of Clinical Endocrinology & Metabolism 84(8):2705 11.
- ↑ Llewellyn, William. 2017. William Llewellyn's Anabolics. Jupiter, FL: Molecular Nutrition, LLC.
- ↑ 3.0 3.1 3.2 3.3 3.4 Anon. n.d. “Oxandrolone Tablets, USP.” FDA Gov. Retrieved (https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/076761lbl.pdf)
- ↑ Porro, Laura J. et al. 2012. “Five-Year Outcomes after Oxandrolone Administration in Severely Burned Children: A Randomized Clinical Trial of Safety and Efficacy.” Journal of the American College of Surgeons 214(4):489–502.
- ↑ 5.0 5.1 5.2 Mozayani, Ashraf and Lionel Raymon. 2016. Handbook of Drug Interactions a Clinical and Forensic Guide. Totowa: Humana Press.
- ↑ 6.0 6.1 NIH. 2018. “Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report.” Retrieved (https://nida.nih.gov/publications/research-reports/steroids-other-appearance-performance-enhancing-drugs-apeds/introduction).
Created by:
Khashayar ( Khash ) Farzam on 12 July 2019 02:43:43
Authors:
Last edited:
7 August 2025 18:48:34
Category: